study

share this:

JNNP: Efficacy and Safety of Cannabinoid Oromucosal Spray for Multiple Sclerosis Spasticity


Efficacy and Safety of Cannabinoid Oromucosal Spray for Multiple Sclerosis Spasticity


Journal of Neurology, Neurosurgery, & Psychiatry:

This study describes the efficacy and safety of a cannabinoid oromucosal spray containing equal amounts of cannabidiol (CBD) and tetrahydrocannabinol (THC) for MS-related spasticity. This publication reports outcomes for 1,615 patients with multiple sclerosis who were included in a patient registry in Italy and treated with the cannabinoid oromucosal spray. This spray is approved in many countries outside of the US for MS-related spasticity.

Source: Journal of Neurology, Neurosurgery, & Psychiatry:

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. F Patti et al., J Neurol Neurosurg Psychiatry, 2016  doi:10.1136/jnnp-2015-312591

http://jnnp.bmj.com/content/ea...

share this: